Cathay Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	8,106	5,347	5,390	6,295	9,629	5,710
Trading Asset Securities	901.8	0.47	0.47	0.47	0.47	1,330
Cash & Short-Term Investments	9,008	5,347	5,391	6,295	9,629	7,040
Cash Growth	94.24%	-0.81%	-14.37%	-34.62%	36.78%	474.40%
Accounts Receivable	685.64	459.88	385.52	463.56	275.22	294.95
Other Receivables	6.32	10.56	10.35	11.79	6.58	8.32
Receivables	691.96	470.43	395.88	475.35	281.8	303.27
Inventory	1,285	1,181	1,466	1,574	1,185	775.1
Prepaid Expenses	-	7.29	10.57	-	-	0.14
Other Current Assets	505.64	381.4	307.18	131.44	298.68	325.91
Total Current Assets	11,491	7,387	7,571	8,475	11,395	8,444
Property, Plant & Equipment	10,088	9,849	9,376	6,670	2,969	2,789
Long-Term Investments	151.24	133.78	142.73	49.51	53.21	56.18
Other Intangible Assets	685.34	685.04	703.85	777.87	768.46	228.44
Long-Term Deferred Tax Assets	254.15	210.37	158.88	88.28	52.2	36.65
Long-Term Deferred Charges	3.81	6.42	4.98	7.17	9.58	7.87
Other Long-Term Assets	771.24	750.4	876.48	1,759	938.51	572.25
Total Assets	23,445	19,021	18,833	17,827	16,185	12,135
Accounts Payable	1,395	135.44	167.85	240.08	248.83	205.25
Accrued Expenses	18.55	30.32	21.54	32.47	42.34	35.66
Short-Term Debt	71.75	1,247	746.25	161.47	743.51	-
Current Portion of Long-Term Debt	9.72	37.17	784.37	5.38	-	-
Current Income Taxes Payable	47.04	32.94	55.54	30.7	45.4	19.28
Current Unearned Revenue	26.6	35.81	10.48	17.81	14.64	19.9
Other Current Liabilities	86.96	1,399	1,624	936.28	123.01	154.68
Total Current Liabilities	1,656	2,918	3,410	1,424	1,218	434.77
Long-Term Debt	197.75	613.26	245.33	960.5	-	-
Long-Term Unearned Revenue	374.25	389.29	405.18	404.39	293.03	214.6
Long-Term Deferred Tax Liabilities	0.2	-	-	-	-	1.37
Total Liabilities	2,228	3,920	4,060	2,789	1,511	650.74
Common Stock	721.29	583.38	583.38	583.28	416.68	416.68
Additional Paid-In Capital	14,302	8,520	8,526	8,540	8,688	8,681
Retained Earnings	2,709	2,546	2,167	1,905	1,539	1,278
Treasury Stock	-155.63	-155.13	-126.19	-94.67	-	-
Comprehensive Income & Other	21.94	12.77	14.45	14.69	8.23	8.68
Total Common Equity	17,598	11,507	11,164	10,949	10,652	10,385
Minority Interest	3,619	3,594	3,609	4,089	4,022	1,100
Shareholders' Equity	21,217	15,101	14,773	15,038	14,674	11,484
Total Liabilities & Equity	23,445	19,021	18,833	17,827	16,185	12,135
Total Debt	279.23	1,897	1,776	1,127	743.51	-
Net Cash (Debt)	8,729	3,450	3,615	5,168	8,886	7,040
Net Cash Growth	161.38%	-4.56%	-30.05%	-41.84%	26.22%	660.78%
Net Cash Per Share	13.47	5.93	6.21	8.87	15.24	12.97
Filing Date Shares Outstanding	704.47	718.95	581.32	582.15	583.35	583.35
Total Common Shares Outstanding	704.47	582.75	581.68	582.15	583.35	583.35
Working Capital	9,835	4,469	4,161	7,051	10,177	8,010
Book Value Per Share	24.98	19.75	19.19	18.81	18.26	17.80
Tangible Book Value	16,913	10,822	10,460	10,171	9,883	10,156
Tangible Book Value Per Share	24.01	18.57	17.98	17.47	16.94	17.41
Buildings	-	1,958	1,815	1,357	988.18	599.56
Machinery	-	3,330	3,216	2,979	1,807	1,002
Construction In Progress	-	5,949	5,443	3,164	758.31	1,610

Source: S&P Global Market Intelligence. Standard template. Financial Sources.